NASDAQ: INDPIndaptus Therapeutics Inc Stock
$1.70-0.06 (-3.41%)
Updated Mar 20, 2026
INDP Price
$1.70
Fair Value Price
N/A
Market Cap
$3.81M
52 Week Low
$1.52
52 Week High
$21.84
P/E
-0.08x
P/B
1.21x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.95
Operating Cash Flow
-$15M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INDP Overview
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INDP's potential to beat the market
- INDP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INDP
RankedUnranked of 470
RankedUnranked of 470
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $31.84 | A | |
| $15.36 | A | |
| $180.62 | A |
Be the first to know about important INDP news, forecast changes, insider trades & much more!
INDP News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INDP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INDP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INDP is good value based on its book value relative to its share price (1.21x), compared to the US Biotechnology industry average (4.6x)
P/B vs Industry Valuation
INDP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INDP due diligence checks available for Premium users.
Valuation
INDP fair value
Fair Value of INDP stock based on Discounted Cash Flow (DCF)
Price
$1.70
Fair Value
$0.61
Overvalued by
178.90%
INDP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INDP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
27.63x
Market
30.56x
INDP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.21x
Industry
4.6x
INDP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INDP's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.1M
Profit Margin
0%
INDP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.3M
Liabilities
$6.2M
Debt to equity
1.95
INDP's short-term assets ($9.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INDP's short-term assets ($9.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INDP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INDP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$0.0
Financing
$5.9M
INDP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INDP vs Biotech Stocks
Indaptus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.